|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Alberta Cancer Board |
|---|---|
| Information provided by: | Alberta Cancer Board |
| ClinicalTrials.gov Identifier: | NCT00126867 |
Purpose
Cancers of the colon and rectum are the third most common cancers in Canadian males and females. The initial therapy of colorectal cancer is surgery to remove the cancer and nearby lymph glands. If the cancer has spread to the lymph glands there is a high chance that the cancer will come back. To reduce the risk of the cancer recurring, patients are treated with an anticancer drug capecitabine. This study will determine if a simple blood test can predict which patients are at risk for developing side effects from this chemotherapy. In addition, participants of this study will be followed to determine if this same blood test will predict which patients will have their cancer relapse.
| Condition |
|---|
|
Colon Cancer |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Based Adjuvant Chemotherapy in Colon Cancer Treatment |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Karen Mulder, MD | 780-432-8826 | karenmul@cancerboard.ab.ca |
| Canada, Alberta | |
| Cross Cancer Institute | Recruiting |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Contact: Clinical Research Unit 780-989-8152 clinical_trials_cci@cancerboard.ab.ca | |
| Principal Investigator: Karen Mulder, MD | |
| Principal Investigator: | Karen Mulder, MD | Alberta Cancer Board |
| Principal Investigator: | Michael Sawyer, MD | Alberta Cancer Board |
More Information
| Study ID Numbers: | GI-05-0049 |
| Study First Received: | August 3, 2005 |
| Last Updated: | September 22, 2008 |
| ClinicalTrials.gov Identifier: | NCT00126867 |
| Health Authority: | Canada: Health Canada |
|
thymidylate synthase polymers rapecitabine adjuvant colon cancer |
toxicity Stage II colon cancer Stage III colon cancer adenocarcinoma of the colon |
|
Capecitabine Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Gastrointestinal Neoplasms |
Intestinal Diseases Adenocarcinoma Colonic Neoplasms Intestinal Neoplasms Colorectal Neoplasms |
|
Antimetabolites Neoplasms Antimetabolites, Antineoplastic Neoplasms by Site |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |
